Cardiff Oncology
CRDF
114 hedge funds and large institutions have $90.3M invested in Cardiff Oncology in 2025 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 46 increasing their positions, 22 reducing their positions, and 19 closing their positions.
203% more call options, than puts
Call options by funds: $3.65M | Put options by funds: $1.2M
109% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 22
5% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 19
2% less funds holding
Funds holding: 116 → 114 (-2)
5.54% less ownership
Funds ownership: 48.62% → 43.08% (-5.5%)
11% less capital invested
Capital invested by funds: $102M → $90.3M (-$11.3M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
+$2.69M |
| 2 |
William Blair & Company
Chicago,
Illinois
|
+$2.36M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.87M |
| 4 |
Millennium Management
New York
|
+$1.41M |
| 5 |
Two Sigma Investments
New York
|
+$839K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$16.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.31M |
| 3 |
O
OrbiMed
New York
|
-$1.8M |
| 4 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$1.33M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$927K |
CRDF Hedge Fund Activity: Q2 2025 in Review
114 of the 7,614 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q2 2025, worth a combined $90.3M — down 11% from $102M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of CRDF and 18 opened new positions — a net loss of 1 holder — while 22 trimmed existing stakes and 46 added.
The largest buyer was Laurion Capital Management, adding an estimated $2.69M. The largest seller was Commodore Capital, exiting entirely with an estimated $16.9M sold.
- 114 institutional investors held Cardiff Oncology (CRDF) as of Q2 2025, down from 116 in Q1 2025.
- Funds reported $90.3M of Cardiff Oncology stock for Q2 2025, down 11% quarter-over-quarter.
- 18 funds opened new Cardiff Oncology positions in Q2 2025 and 19 closed out, a net change of -1 holder.
- The largest Cardiff Oncology buyer in Q2 2025 was Laurion Capital Management, an estimated $2.69M added.
- The largest Cardiff Oncology seller in Q2 2025 was Commodore Capital, an estimated $16.9M sold.
Based on aggregated 13F filings for Q2 2025.